Callisto has developed research collaborations with world-renowned scientists to develop its pre-clinical discovery portfolio.

National Cancer Institute:
Callisto presently retains a collaborative research program with scientists at NCI to evaluate the therapeutic potential of Atiprimod in colon, prostate and breast cancers.

Dr. Leonard Forte, Ph.D.
Professor, Department of Biochemistry, University of Missouri, Columbia, MO. One of the discoverers of uroguanylin and the therapeutic applications of GCRA technology to colon cancer and GI inflammation.

Dr. John B. Zabriskie, M.D.
The Rockefeller University, NY. A pioneer in the development of superantigen technology and its therapeutic applications to bioterrorism.